BPI STOPS TIRZEPATIDE Production, Second Major Pharmacy Out!

Major disruption hits the GLP-1 landscape as another large 503B compounding pharmacy halts production of semaglutide and tirzepatide. In this episode, we unpack what’s driving the FDA’s increased enforcement and why these shutdowns could signal a broader shift in the compounded medication market.

Joined by Sabina Hemmi from glpwinner.com, we break down the key differences between 503A and 503B pharmacies, what these changes mean for supply and patient access, and why delays in prescriptions may be on the horizon. We also dive into the growing legal battles between pharma companies and telehealth providers and what that could mean for the future of affordable GLP-1 options.

If you’re using or considering compounded GLP-1s, this episode covers what you need to know right now and what could be coming next.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(193)

Eli Lilly Isn’t Telling Us About Their Future Obesity Drugs

Does Eli Lilly already have the solve for obesity? In this episode of On the Pen — the Weekly Dose Podcast, host Dave Knapp breaks down a stunning comment from Lilly's Chief Scientific Officer Daniel ...

2 Kesä 20min

Retatrutide, Multi Agonist Obesity Drugs, and the PBM Access War

https://linktr.ee/manonthemounjaro

26 Touko 30min

Lilly Bets $8B on Weight Loss Future

https://linktr.ee/manonthemounjaro

19 Touko 23min

The Next Two Weeks in GLP1 Are Huge, Here's Why

http://www.otplinks.com

12 Touko 1h 7min

He Took Retatrutide 40mg and Proved a Point

This episode examines a serious case involving retatrutide, where an individual experienced an overdose due to improper medication administration. We discuss the critical importance of medication safe...

5 Touko 36min

Eli Lilly Earnings Call Recap: Q1 2026

We just got done listening to the quarter one, 2026 Eli Lilly earnings call. There was a lot of information to get into, whether you're interested in retatrutide, eloralintide, or Foundayo, and all of...

30 Huhti 25min

SURVODUTIDE Phase 3 Data: Why Weight Loss Isn't The Whole Story

https://www.otplinks.comA new GLP-1 and glucagon agonist dropped data that was supposed to rival retatrutide, just without the GIP, and on the surface the results look solid. But that is not the real ...

28 Huhti 18min